1. Shay, J. W. & Bacchetti, S. A survey of telomerase activity in human cancer. Eur. J. Cancer 33, 787–791 (1997).
2. Komata, T. et al. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res. 61, 5796–5802 (2001).
3. Breidenbach, M. et al. Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy. Gene Ther. 12, 187–193 (2005).
4. Nettelbeck, D. M., Rivera, A. A., Balague, C., Alemany, R. & Curiel, D. T. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res. 62, 4663–4670 (2002).
5. Chen, J. S. et al. Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther. 11, 740–747 (2004).